Publications
19.11.2020
ISPO 2020 Developing a sustainable biosimilar

To facilitate biosimilar uptake, several mechanisms aimed at reducing the acquisition cost of biosim...

Read more
Publications
19.11.2020
COVID-19 impact on HTA bodies

HTA bodies and companies within the pharmaceutical industry have been forced to react to unprecedent...

Read more
Publications
19.11.2020
ISPOR 2020 New NICE STA process

This study aimed to assess whether the new process has resulted in changes to outcomes of STAs.

Read more
Articles
09.11.2020
NICE STA Process

A recent study assessed whether this new process has resulted in faster patient access.

Read more
Articles
28.10.2020
EMA regulatory decisions after BREXIT

The UK will continue to adopt decisions taken by the European Commission on the approval of new mark...

Read more
Articles
23.10.2020
Sustainable biosimilar marketplaces

To facilitate biosimilar uptake, several mechanisms encouraging biosimilar uptake have been implemen...

Read more
Articles
12.10.2020
What impact has COVID-19 had on HTA bodies

A survey of employees within pricing and market access n pharma and biotech companies.

Read more
News
07.10.2020
Revisiting the influence of ICER in the US

ICER’s Health Technology Assessments review process is an assessment undertaken by one of three ap...

Read more
Articles
17.09.2020
The value of a Global Value Dossier

GVD is a core document, which may be considered the “heart” of the pharmaceutical product’s pa...

Read more
Articles
13.08.2020
What is Health Technology Assessment (HTA)

A multidisciplinary process that uses explicit methods to determine the value of a health technology...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.